Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Cara Therapeutics, Inc. (Nasdaq: CARA) has announced that President and CEO Christopher Posner will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 8:30 a.m. ET. This event highlights the company's commitment to improving the lives of patients with pruritus. Cara’s KORSUVA™ (difelikefalin) injection is the first FDA-approved treatment for moderate-to-severe pruritus in adults on hemodialysis. The company is also advancing oral formulations and conducting Phase 2 and 3 programs for various pruritus conditions.
- None.
- None.
STAMFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, at 8:30 a.m. ET.
A webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.
MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com
INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com
FAQ
When is Christopher Posner's presentation at the H.C. Wainwright Conference?
What is KORSUVA and its significance for Cara Therapeutics?
What recent trials is Cara Therapeutics conducting?
How can I access the webcast of Cara Therapeutics' presentation?
What is the ticker symbol for Cara Therapeutics?
